The National Institute for Health and Care Excellence

Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars

We’re delighted that NICE has approved bevacizumab for first- and second-line treatment in combination with chemotherapy for advanced bowel cancer patients in England and Wales, following a similar ...
National Institute for Health and Care Excellence

Topic prioritisation

Menotrophin prefilled pen for treating anovulation or during controlled ovarian hyperstimulation [TSID12290] Medicines evaluation Not selected 12 December 2025 Cyclosporin eye drops for treating ...
National Institute for Health and Care Excellence

Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

There is a simple discount patient access scheme for talquetamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia

There is a simple discount patient access scheme for obe-cel. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...
National Institute for Health and Care Excellence

Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]

Suggested remit: To appraise the clinical and cost effectiveness of givinostat within its marketing authorisation for treating Duchenne muscular dystrophy in people 6 years and over. Anticipate the ...